Product Program year 2025 Source: CMS Open Payments

Gilenya

Drug Neurology

NDC 0078-0607-15

Open in the dashboard

General payments

$74,020

231 payments

Research payments

$31,462

18 payments

Through program year 2025, $74,020 in general payments and $31,462 in research payments were reported against Gilenya (Neurology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2025 General $749 8
2025 Research $1,050 2
2024 General $58 4
2024 Research $18,126 6
2023 General $73,214 219
2023 Research $12,286 10

Breakdown

Who paid General payments · program years 2023–2025
  1. Novartis Pharmaceuticals Corporation $73,382 230 payments
  2. Novartis Pharma AG $638 1 payment
Top recipients General payments · program year 2025
  1. Bruce Cree Neurology · San Francisco, CA $638 85% · 1 payment
  2. John Pierpont Neurology · Tucson, AZ $19 3% · 1 payment
  3. Warren Spinner Neurology · Port Jefferson Station, NY $15 2% · 1 payment
  4. Jennifer Ahmed Neurology · Plainview, NY $15 2% · 1 payment
  5. Beth Silverstein Neurology · Glen Cove, NY $15 2% · 1 payment

The top 5 of 8 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Neurology Psychiatry & Neurology $718 96% · 6 practitioners
  2. Physician Assistant $15 2% · 1 practitioner
  3. Physician Assistant, Medical Physician Assistant $15 2% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. California $638 85% · 1 recipient
  2. New York $76 10% · 5 recipients
  3. Arizona $19 3% · 1 recipient
  4. Florida $15 2% · 1 recipient

Each share is of general payments naming this product in 2025 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

2,619

Prescriptions dispensed, refills included

Drug cost

$28,299,944

Paid at the pharmacy, in all

Prescribers

158

With 11 or more claims of it

Medicare Part D drugs matched to GILENYA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Gilenya Fingolimod Hcl Same name 158 2,619 $28,299,944

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Angel Chinea Neurology PR 110 $1,160,202 None on record
Randall Trudell Neurology TN 82 $849,875 None on record
Randall Webb Neurology OK 51 $562,904 None on record
Christopher Laganke Neurology AL 44 $463,995 None on record
Harold Moses Neurology TN 39 $368,023 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
231 general · 18 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record